These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26628375)

  • 1. GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.
    Poirier S; Mamarbachi M; Chen WT; Lee AS; Mayer G
    Cell Rep; 2015 Dec; 13(10):2064-71. PubMed ID: 26628375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
    Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
    Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
    PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
    DeVay RM; Yamamoto L; Shelton DL; Liang H
    PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
    Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
    Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
    Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
    Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
    J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local effects of human PCSK9 on the atherosclerotic lesion.
    Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
    J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
    Tveten K; Holla ØL; Cameron J; Strøm TB; Berge KE; Laerdahl JK; Leren TP
    Hum Mol Genet; 2012 Mar; 21(6):1402-9. PubMed ID: 22156580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
    Maxwell KN; Fisher EA; Breslow JL
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.